Literature DB >> 27408383

Synchronous Plasma Cell Myeloma and Acute Myeloid Leukemia in a Therapy-Naïve Patient: A Rare Occurrence.

Rajesh Kumar1, Vishrut K Srinivasan1, Prashant Sharma2, Ritu Aggarwal3, Gaurav Prakash4, Pankaj Malhotra4, Neelam Varma2.   

Abstract

Plasma cell proliferations in patients with acute myeloid leukemia (AML) are rare, whether at presentation or during or after therapy. Interpretation requires correlation with the clinical background, drug history as well as inputs from tests for monoclonal gammopathy and end-organ damage. The major diagnostic issues stem from excluding myeloma alone with a plasmablastic morphology that mimics AML as well as reactive or polyclonal plasmacytosis occurring in a bonafide case of AML alone before rendering a rare diagnosis of true dual pathologies. We report a rare case of concurrent AML and plasma cell myeloma in a 55-year-old lady that posed a significant diagnostic challenge. The patient had significant co-morbidities complicating the clinical picture and was treatment-naïve at the time of diagnosis. Our approach to confirming the diagnosis, as well the challenges faced in flow cytometric analyses are highlighted. The pathogenesis of such dual pathologies remains unresolved, although various conjectures and theories have been propounded in literature.

Entities:  

Keywords:  Acute myeloid leukemia; Multiple myeloma; Plasma cell myeloma; Plasmacytosis

Year:  2015        PMID: 27408383      PMCID: PMC4925541          DOI: 10.1007/s12288-015-0628-9

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  18 in total

1.  Simultaneous acute myeloid leukemia and multiple myeloma successfully treated with allogeneic stem cell transplantation.

Authors:  Daniel Kim; Brian Kwok; Amir Steinberg
Journal:  South Med J       Date:  2010-12       Impact factor: 0.954

2.  Reactive plasmacytic lesions of the bone marrow.

Authors:  B H Hyun; D Kwa; H Gabaldon; J K Ashton
Journal:  Am J Clin Pathol       Date:  1976-06       Impact factor: 2.493

3.  Clinical significance of plasmacytosis in the day+14 bone marrow of patients with acute myeloid leukaemia undergoing induction chemotherapy.

Authors:  Nada Al-Shughair; Ghuzayel Al-Dawsari; Martin Gyger; Gamal Mohamed; George Roberts
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

4.  Simultaneous occurrence of acute myeloblastic leukaemia and multiple myeloma without previous chemotherapy.

Authors:  T Tursz; G Flandrin; J C Brouet; J Briere; M Seligmann
Journal:  Br Med J       Date:  1974-06-22

5.  Reactive plasmacytosis. Case report and review of the literature.

Authors:  P Gavarotti; M Boccadoro; V Redoglia; F Golzio; A Pileri
Journal:  Acta Haematol       Date:  1985       Impact factor: 2.195

6.  Bone marrow findings of reactive plasmacytosis.

Authors:  C T Liu; M B Dahlke
Journal:  Am J Clin Pathol       Date:  1967-12       Impact factor: 2.493

7.  Simultaneous presentation of multiple myeloma and acute monocytic leukemia.

Authors:  Dragos C Luca; Imad Y Almanaseer
Journal:  Arch Pathol Lab Med       Date:  2003-11       Impact factor: 5.534

8.  Plasmacytosis in acute myeloid leukemia: two cases of plasmacytosis and increased IL-6 production in the AML blast cells.

Authors:  G G Wulf; G Jahns-Streubel; B Hemmerlein; K Bonnekessen; B Wörmann; W Hiddemann
Journal:  Ann Hematol       Date:  1998-06       Impact factor: 3.673

9.  Simultaneous occurrence of multiple myeloma and acute myeloid leukemia.

Authors:  Suresh Attili; K C Lakshmiah; M Madhumati; Kamal S Saini; G Anupama; Monika Lamba Saini; T P Sahoo
Journal:  Turk J Haematol       Date:  2006-12-05       Impact factor: 1.831

10.  A case of acute promyelocytic leukemia concomitant with plasma cell myeloma.

Authors:  Jinsook Lim; Gye Cheol Kwon; Sun Hoe Koo; Ik Chan Song; Jimyung Kim
Journal:  Ann Lab Med       Date:  2014-02-13       Impact factor: 3.464

View more
  1 in total

1.  Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size.

Authors:  Celine Berthon; Morgane Nudel; Eileen M Boyle; Laure Goursaud; Thomas Boyer; Alice Marceau; Bruno Quesnel
Journal:  Leuk Res Rep       Date:  2020-04-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.